Business Overview: Valion Bio, Inc. (NASDAQ: VBIO)

---

Executive Summary

Valion Bio, Inc. — known through its FY2024 Form 10-K as Tivic Health Systems, Inc. before its rebrand — describes itself as a "diversified therapeutics company" running two very different programs under one roof: a commercial bioelectronic device business and an early-stage biologics (immunotherapeutics) pipeline. Headquartered in Fremont, California, and operating with a lean staff of seven full-time employees and two contractors as of year-end 2024, the company generates modest revenue today from its over-the-counter ClearUP sinus-relief device while pursuing two much larger, binary bets: a neurostimulation platform and a licensed late-stage biologic for acute radiation syndrome.

Originally incorporated in California in September 2016 and reincorporated in Delaware in June 2021, the company has disclosed going-concern doubt about its ability to fund operations for the next twelve months — a risk profile typical of a small, pipeline-heavy therapeutics company still searching for its first major commercial or partnership catalyst.

---

1. Core Business Model & How They Work

[ ClearUP OTC Device Sales ] ➡️ [ Cash to Fund Pipeline ] ➡️ [ ncVNS Clinical Research + Entolimod BLA Prep ] ➡️ [ Partnership/Licensing or Approval ]

Key Operational Drivers

1. Commercial Bioelectronic Product (ClearUP): A handheld, FDA-cleared/De Novo over-the-counter device using ultra-low-current electrical waves to relieve sinus pain and congestion, sold direct via the company website and through Amazon, Walmart, and Target. As a cash-pay consumer product with no government or private insurance reimbursement, the company has deliberately kept sales expansion gradual to protect pricing.
2. Non-Invasive Vagus Nerve Stimulation (ncVNS) Research: An early research-stage platform being evaluated with the Feinstein Institute (Northwell Health), where initial studies reported increased heart rate variability and EEG/pupil changes. A second study is examining stimulation parameters, with target indications still being prioritized ahead of trials planned for 2025.
3. Licensed Late-Stage Biologic (Entolimod): In February 2025, the company licensed Entolimod, a recombinant TLR5 agonist for acute radiation syndrome, worldwide and exclusively from Statera Biopharma, along with an option on five additional indications and the second-generation product Entolasta. Entolimod already carries FDA Fast Track and Orphan Drug designations, and the company's immediate focus is manufacturing validation and preparing a Biologics License Application (BLA) — a much later-stage, lower-clinical-risk asset than a typical pipeline addition.
4. Asset-Light Manufacturing: ClearUP relies on off-the-shelf components, many sourced from China, built through third-party manufacturing and distribution under the company's ISO 13485 certification — keeping fixed costs low for a company of this size.

---

2. Business Segments

Valion Bio does not report formal operating segments; its business is best understood as three distinct programs at very different stages of maturity, which this section presents in place of a segment breakdown that the company itself does not use:

┌─────────────────────────────────┐
│          Valion Bio, Inc.          │
└────────────────┬────────────────────┘
                  │
   ┌──────────────┼───────────────┬──────────────────┐
   ▼                ▼               ▼
┌──────────┐  ┌───────────────┐  ┌──────────────────┐
│  ClearUP   │  │     ncVNS       │  │     Entolimod       │
│(commercial,│  │  (research-     │  │  (licensed Feb 2025, │
│ cash-pay)  │  │   stage,        │  │   BLA-track, FDA     │
│            │  │   Feinstein     │  │   Fast Track/Orphan) │
│            │  │   Institute)    │  │                      │
└──────────┘  └───────────────┘  └──────────────────┘

---

3. Product Portfolio

---

4. Competitive Landscape

   THREE SEPARATE COMPETITIVE ARENAS
┌──────────────────────────────────────────────────────┐
│ ClearUP:     Analgesics, decongestants, nasal steroids,│
│              saline irrigation — mostly cheap, familiar │
│              OTC alternatives, not device competitors   │
│                                                           │
│ ncVNS:       Implanted vagus nerve stimulators dominate; │
│              Valion is non-invasive, a different approach│
│                                                           │
│ Entolimod:   FDA-approved hematopoietic syndrome drugs   │
│              (Neupogen, Neulasta) + other radiation       │
│              countermeasure developers                    │
└──────────────────────────────────────────────────────┘

• ClearUP competes less against other medical devices than against cheap, familiar over-the-counter remedies: ibuprofen, acetaminophen, naproxen, intranasal steroids, and saline irrigation — a crowded, low-switching-cost category where Valion is a small share player.
• ncVNS would compete against implanted vagus nerve stimulators, the dominant technology in a market the company estimates at $21 billion; Valion's differentiation is being non-invasive rather than surgically implanted.
• Entolimod competes against FDA-approved hematopoietic syndrome treatments like Neupogen and Neulasta, as well as other radiation countermeasure developers targeting government stockpiling contracts.

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• FDA-Cleared Commercial Product: ClearUP's regulatory clearance and established retail distribution (Amazon, Walmart, Target) give the company a real, if small, revenue base most pre-revenue biotechs lack.
• De-Risked Biologics Addition: Licensing Entolimod — already carrying FDA Fast Track and Orphan Drug status — gives the company a later-stage, lower-clinical-risk asset than building a biologic from scratch.
• Capital-Light Operating Model: Seven full-time employees and outsourced manufacturing keep fixed costs low relative to the breadth of programs being pursued.

Strategic Risks & Vulnerabilities

1. Going Concern Doubt: The company has explicitly disclosed that its cash may be insufficient for the next twelve months, raising substantial doubt about its ability to continue as a going concern — the central risk overhanging the entire business.
2. Dilution Risk: Funding three simultaneous programs (a mature OTC product, early-stage research, and a BLA-track biologic) on a small balance sheet will likely require additional equity raises that could meaningfully dilute existing shareholders.
3. Unproven ncVNS Commercial Strategy: The company has not yet set a sales strategy for ncVNS and has made no Entolimod sales or marketing efforts — both programs remain commercially undefined even where clinical progress exists.
4. Manufacturing Concentration: ClearUP's reliance on off-the-shelf components sourced largely from China introduces supply-chain and geopolitical risk to the company's only current revenue stream.
5. Material Weakness in Internal Controls: The company has disclosed a material weakness tied to staffing levels, a governance flag investors should weigh alongside the clinical and financing risks.

---

6. Financial Overview

---

7. Summary Conclusion

Valion Bio is a small, capital-constrained therapeutics company juggling a modest but real commercial device business against two much larger, binary-outcome bets: an early-stage non-invasive neurostimulation platform and a newly licensed, later-stage biologic for acute radiation syndrome. The Entolimod license is a genuinely interesting strategic move — it imports a de-risked, designation-bearing asset rather than starting biologics development from zero — but the company's disclosed going-concern doubt means the central question for the business isn't scientific promise so much as whether it can raise enough capital, without excessive dilution, to reach its next meaningful clinical or regulatory milestone.